Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digoxin for Reinduction of Radioiodine Uptake in Non-medullary Thyroid Carcinoma
2022-500477-14-00Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of digoxin in Non-medullary thyroid cancer (NMTC) and Non-medullary thyroid carcinoma (NMTC), sponsored by Radboud University Medical Center. Primary endpoint: Reinduction of radioiodine uptake in radioiodine-refractory target lesions. Started Aug 2022; status: completed.
02
Drugs
digoxin
03
Conditions
Non-medullary thyroid cancer (NMTC)Non-medullary thyroid carcinoma (NMTC)
Beyond the preview
Go deeper on 2022-500477-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500477-14-00.